Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169413 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1168721 | 0.88 | TP53 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1168722 | 0.88 | TP53 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1169335 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1169337 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1169493 | 0.86 | PSEN1 (0.56) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1169489 | 0.86 | PSEN1 (0.56) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1168833 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1169097 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL1168832 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | claimed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | claimed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | claimed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | claimed |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE | 2002-12-05 | — | — | US | claimed |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7842718-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050196813-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-09-08 | — | — | US | disclosed |
| US-6878742-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-04-12 | — | — | US | disclosed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, PSEN1 | ALDH1A1 3387/4885LMNA 1423/4885HTT 17/4885 |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | ALDH1A1 3387/4885LMNA 1423/4885HTT 17/4885 |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | ALDH1A1 2994/4885LMNA 1273/4885HTT 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.